According to a new study funded by the state of Alabama, patients in Alabama with intractable epilepsy felt better overall within one year of beginning CBD therapy even in the face of declining social support and stressful events. Although lead researcher Barbara Hansen did admit she cannot definitively point to CBD as the agent producing relief, she did confirm each patient in the study was administered CBD. In this open-label study, researchers from the University of Alabama at Birmingham distributed 100 mg/ml CBD solutions to patients. The study involved a range of participants aged 1-63 years old, and it took place for just over two years between the years of 2015 and 2017.
Participants initially started with doses of 5mg of this solution for every kg of their weight on a daily basis, divided into two spoonfuls. Every two weeks they had the opportunity to increase their dose by 5 mg, with a maximum at 50 mg/kg a day. They then were asked to complete the Interpersonal Support Evaluation List, and a measure from a 0-1 scale perception of their overall health. One year later, 77.4% of participants reported good feelings, compared to 73.3% at the beginning. Overall, patients reported .2-3 points of decline in their ISEL scores despite reporting an average of .29 increase in stressful events. Children witnessed a decrease in stressful events by .86. Some patients withdrew from the study before their followup surveys, and although the study began with 135, the data collected came from only 62 patients who continued in the study. This study will continue.
This information has been provided by Leafly and approved by our Chief Medical Officer.